La vendita allo scoperto per Vivos dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Vivos. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Vivos (OTC:RDGL) Azioni, Report sulle vendite allo scoperto

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Vivos Inc

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) with a Outperform and raises the price target from $117 to $120.

News

Price Target

Analyst Ratings

PLMR

Keefe, Bruyette & Woods Maintains Outperform on Palomar Hldgs, Raises Price Target to $120

Shares To Trade On Nasdaq Under Symbol JTAI With New CUSIP

Stock Split

JTAI

Jet.AI To Implement 1-For-225 Reverse Stock Split, Effective Nov. 12

JP Morgan analyst Doug Anmuth maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $135 to $170.

EXPE

JP Morgan Maintains Neutral on Expedia Group, Raises Price Target to $170

Universal Health Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) short percent of float has risen 8.54% since its last report. The company recently reported that it has 1.53 million shares sold short, which is 3.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.89 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Universal Health Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731084320_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Universal Health Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Universal Health Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Universal Health Servs's peer group average for short interest as a percentage of float is 4.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(UHS) - Analyzing Universal Health Servs's Short Interest

Inno Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NYSE">INHD</a>) short percent of float has risen 258.33% since its last report. The company recently reported that it has 34 thousand shares sold short, which is 6.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Inno Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731084315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Inno Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Inno Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Inno Holdings's peer group average for short interest as a percentage of float is 2.97%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

INHD

Looking Into Inno Holdings's Recent Short Interest

Accenture's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) short percent of float has risen 3.12% since its last report. The company recently reported that it has 6.19 million shares sold short, which is 0.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Accenture Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731084310_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Accenture has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Accenture's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Accenture's peer group average for short interest as a percentage of float is 3.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Accenture's Recent Short Interest

SBGI

Sinclair And IIT Bombay Partner On Wireless Broadcast-to-Everything (B2X) Research; MoU To Enhance ATSC 3.0 Standard For Mobile, TV, And IoT Applications With 5G Integration And Low-Latency Datacasting

Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) announced today that the Board of Directors has formally authorized an additional $300 million for stock repurchase under Chemed's existing share repurchase program. These share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility.

Buybacks

Chemed Authorizes An Additional $300M For Stock Repurchase

Keefe, Bruyette &amp; Woods analyst Timothy Switzer reiterates NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) with a Market Perform and raises the price target from $13 to $15.

Reiteration

NEWT

Keefe, Bruyette & Woods Reiterates Market Perform on NewtekOne, Raises Price Target to $15

HC Wainwright &amp; Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) with a Buy and maintains $5 price target.

PRLD

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target

Shares of Airbnb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) tumbled in early trading on Friday, after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41825994/airbnb-stock-down-on-q3-earnings-building-on-robust-momentum-in-september-we-are-off-to-a-great-sta">downbeat third-quarter results</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Piper Sandler On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5981fdcbc1f558000155e858/thomas-champion">Analyst Thomas Champion</a> maintained a Neutral, while raising the price target from $125 to $145.
Airbnb reported third-quarter gross bookings and revenues of $20.1 billion and $3.7 billion, up 10% year-on-year and 9% year-on-year, respective, with both coming in higher than estimates, Champion said in a note. The company's results were "solid" and reflected "firming demand trends," he added.
Airbnb repurchased shares worth around $1.1 billion, higher than its average of $500 million in the first and second quarters, with remaining authorization of $4.2 billion, the analyst stated. Management indicated expenses in marketing and investment in new businesses "to reignite growth," he further wrote.
JPMorgan On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591479b8290fa7000138e4b4/doug-anmuth">Analyst Doug Anmuth</a> reiterated a Neutral rating, while lifting the price target from $121 to $142.
Despite the challenges faced in the second quarter, "broad-based strength in demand trends &amp; a normalization of booking lead times" generated growth in GBV (gross booking value) through the third quarter and into the fourth, Anmuth said.
The company's fourth-quarter guidance of N&amp;E (Nights &amp; Experiences) acceleration "reflects continued healthy travel demand trends, a normalized booking window relative to last quarter, and success across core optimizations and market expansion, despite tougher comps," the analyst wrote. With investments in marketing and product development expected to continue through 2025, Airbnb's margins could remain under pressure in the near term, he added.
Goldman Sachs On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e33195064ed000173030b/eric-sheridan">Analyst Eric Sheridan</a> reiterated a Sell, raising the price target from $103 to $107.
Airbnb indicated demand strength into the fourth quarter across its core and expansion markets, which build on "demand accelerating every month since July," Sheridan said. The company's revenue guidance for the fourth quarter reflects "an acceleration in room nights/experiences booked compared to Q3," he stated.
"Lead times have now normalized globally exiting Q3 and mgmt. pointed to factors like the Olympics contributing to softness in long lead time bookings at the start of the quarter," the analyst wrote. He added, however, that investments in long-term platform expansion efforts "created upward pressure on expenses (esp. marketing and product) into Q4," resulting in uncertainty around the company's margins in 2025.
Wedbush On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58459503ee7bf6000154d075/scott-devitt">Analyst Scott Devitt</a> maintained an Outperform rating, while upping the price target from $135 to $155.
While reporting better-than-expected third-quarter results, Airbnb provided "a mixed outlook," Devitt said. The company's 2024 adjusted EBITDA margin guidance of approximately 35.5% implies fourth-quarter margins of about 27%, below the consensus of 29.7%, he added.
Margins will come under pressure as the company "continues to invest in marketing as well as product teams in advance of upcoming launches next year," the analyst stated. There are several potential catalysts in 2025, including mix shift to higher growth expansion markets, "take rate expansion supported by monetization improvements and new host/guest services, and growth beyond the core," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Truist Securities On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59e8ba80efacff0001417468/patrick-scholes">Analyst Patrick Scholes</a> reiterated a Hold rating and price target of $124.
Better-than-expected margins drove Airbnb's EBITDA to $100 million, higher than Street estimates, Scholes said. He added, however, that the situation is likely to reverse in the fourth quarter, as the guidance implies margins around 300 basis points (bps) lower than consensus.
Nonetheless, the third-quarter results and fourth-quarter earnings guidance indicate full-year adjusted EBITDA above the consensus, the analyst stated. Booking lead times normalized as the year progressed and the company did not mention signs of slowing demand in the U.S. like it had during its second-quarter release, he said.
Benchmark On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d3cdb7b85e930001808a59/daniel-kurnos">Analyst Daniel Kurnos</a> reaffirmed a Buy rating and price target of $155.
Airbnb delivered "a solid, all-around quarter," with every metric modestly beating consensus expectations, Kurnos said. The company's third-quarter "bodes well for our previously non-consensus, almost double-digit nights and experiences call for 4Q," he added.
The analyst stated, however, that Airbnb remains in "the sentiment penalty box after a couple of tough prints," which is why its stock declined when the fourth-quarter margin guidance came in below Street expectations. 
The company's plans to launch several new "billion dollar standalone" businesses, investments in non-core market growth, and commentary on adding hotels on the platform "probably spooked the cash flow crowd a bit as well," he further wrote.
Needham On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587635595064ed000140010c/scott-berg">Analyst Bernie McTernan</a> maintained a Hold rating on the stock.
Nights booked grew by 8.5% year-on-year in the third quarter, slowing by 20 bps sequentially, McTernan said. Despite a slow start to the quarter, "demand grew each month of 3Q, accelerating every month and into October," he added.
"The company attributed this to more normalized lead times, app bookings growth (58% of nights booked vs 53% YoY), and new first time bookers," the analyst wrote. Comps will get easier in September and October relative to November and December, and year-on-year trends are likely to stabilize, he stated.
Oppenheimer On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ef86f00bd9910001e5afe6/jed-kelly">Analyst Jed Kelly</a> reaffirmed a Perform rating on the stock.
Although Airbnb's nights-booked decelerated sequentially by around 20 bps in the third quarter, this was better than Street&#8217;s expectations of 150 bps, Kelly said. The better-than-anticipated performance was due to strength in the Latin America and Asia Pacific regions, he added.
The company guided to fourth-quarter revenue of $2.39-$2.44 billion, which implies an acceleration in nights booked and bookings growth of 10%-12% year-on-year, the analyst stated. The full-year EBITDA margin guide of 35.5% implies "4Q EBITDA $642M, 26.6% margins contracting 670bps-y/y driven by S&amp;M/ Product deleverage and lower take-rates from gift cards," he further wrote.
ABNB Price Action: Shares of Airbnb were down 8% to $135.56 at the time of publication on Friday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/real-estate/24/10/41233338/i-make-180-000-a-month-off-properties-i-dont-even-own-airbnb-arbitrage-is-a-golden-goose-for-many-yo">&#8216;I Make $180,000 A Month off Properties I Don&#8217;t Even Own&#8217; – Airbnb Arbitrage Is A Golden Goose For Many Young Hustlers</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings Beats

Travel

Movers

Real Estate

ABNB

Airbnb's Margins Under Pressure Despite Q3 Beat, Analysts Caution

JP Morgan analyst Paul Coster maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Overweight and lowers the price target from $20 to $15.

ARRY

JP Morgan Maintains Overweight on Array Technologies, Lowers Price Target to $15

Legal

Global

ASML

ASML, Tokyo Electron Queried By U.S. Lawmakers On Sales To China

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Outperform and raises the price target from $30 to $33.

Keefe, Bruyette & Woods Maintains Outperform on Marex Group, Raises Price Target to $33

JP Morgan analyst Reginald Smith maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $47 to $56.

AFRM

JP Morgan Maintains Overweight on Affirm Holdings, Raises Price Target to $56

HC Wainwright &amp; Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) with a Buy and maintains $7 price target.

PBYI

HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target

JP Morgan analyst Tien-Tsin Huang maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Neutral and raises the price target from $28 to $36.

TOST

JP Morgan Maintains Neutral on Toast, Raises Price Target to $36

Guidance

Fluor During Conference Call, Said Company 'Four Quarters Behind' Its Prior 2026 EBITDA Target

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Corpay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) with a Outperform and raises the price target from $380 to $400.

CPAY

Keefe, Bruyette & Woods Maintains Outperform on Corpay, Raises Price Target to $400

JP Morgan analyst Rahul Krotthapalli maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Overweight and raises the price target from $80 to $90.

PLNT

JP Morgan Maintains Overweight on Planet Fitness, Raises Price Target to $90

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
I cannot stress enough how risky OTC stocks or securities traded over the counter really are. For one thing, just the name OTC should ring some alarm bells. This designation means that these securities don&rsquo;t trade on exchanges like the New York Stock Exchange or the Nasdaq. Instead, they trade via broker-dealer networks. And not all stock platforms support what&rsquo;s otherwise known as the pink sheets.



Second, many investors are shocked to discover the administrative costs tied to OTC stocks. Yes, many of these securities are &ldquo;cheap,&rdquo; trading hands at unit prices well below a buck. However, that doesn&rsquo;t mean that it&rsquo;s cheap to you. Wide bid-ask spreads may mean that your holdings may have to rise significantly higher to be net profitable. Also, even if you are profitable, low trading volume could mean a long time to find a buyer.



At the same time, OTC stocks or otherwise highly speculative shares can fly higher. Some <a href="https://www.gobankingrates.com/investing/stocks/most-successful-penny-stocks-ever/">examples</a> include the following:



<ul><li>Monster Beverage (NASDAQ:<a href="https://investorplace.com/stock-quotes/mnst-stock-quote/">MNST</a>): In 1997, you could have had MNST for just two cents.</li>



<li>Apple (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/">AAPL</a>): On a split-adjusted basis, you could have bought AAPL for 10 cents in December 1980.</li>



<li>Advanced Micro Devices (NASDAQ:<a href="https://investorplace.com/stock-quotes/amd-stock-quote/">AMD</a>): Back in June 2015, AMD traded for below $2.</li>
</ul>Of course, there are way more failures than successes. But if you want to go for gold, below are the OTC stocks to consider.



<h2>Tencent (TCEHY)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/tcehy-stock-3-300x169.jpg" alt="Tencent (TCEHY) sign on Tencent headquarters in Shenzhen, China."><div>Source: StreetVJ / Shutterstock.com</div></div>


A Chinese multinational technology conglomerate, Tencent (OTCMKTS:<a href="https://investorplace.com/stock-quotes/tcehy-stock-quote/">TCEHY</a>) has had a rough outing in 2023. Mainly, that&rsquo;s due to the challenging circumstances surrounding the Chinese economy. And if a CNN report proves correct, 2024 <a href="https://www.cnn.com/2023/12/27/economy/china-economy-challenges-2024-intl-hnk/index.html">could be an even rougher outing</a>. Still, Tencent&rsquo;s <a href="https://www.reuters.com/technology/tencent-reveals-most-ambitious-game-yet-consoles-amid-global-expansion-2023-12-08/">expansionary ambitions</a> reach beyond its home nation. With eyes on Japan, South Korea, Southeast Asia, and <a href="https://www.prnewswire.com/apac/news-releases/tencent-cloud-highlights-collaborative-global-expansion-with-digital-ecological-partners-at-tencent-cloud-digital-ecosystem-summit-2023-global-connect-session-301921841.html#:~:text=Fred%20Sun%2C%20General%20Manager%20of,East%2C%20providing%20solutions%20for%20various">several other international regions</a>, Tencent could be interesting for speculators.



To be sure, with a market capitalization of around $337.5 billion, TCEHY doesn&rsquo;t exactly rate as one of the typical OTC stocks. However, it&rsquo;s a great confidence booster because it&rsquo;s in some ways the best of both worlds: offering tremendous upside potential while also being a technology stalwart in its home nation.



Analysts rate shares a <a href="https://www.tipranks.com/stocks/tcehy">consensus moderate buy</a> with a $49.56 average price target. That implies an upside potential of over 40%. What&rsquo;s more, the high-side target hits $61.13, possibly delivering growth of over 73%. If that wasn&rsquo;t enough to whet your appetite, shares <a href="https://www.gurufocus.com/stock/TCEHY/summary?search=tcehy">trade at only 13.06X forward earnings</a>, below the interactive media sector&rsquo;s median value of 21.19X.



<h2>BYD (BYDDF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/byddf-stock-1-300x169.jpg" alt="A close-up view of the power supply plugged into a vehicle from BYD Company (BYDDY)."><div>Source: J. Lekavicius / Shutterstock.com</div></div>


Moving on to another Chinese company, BYD (OTCMKTS:<a href="https://investorplace.com/stock-quotes/byddf-stock-quote/">BYDDF</a>) presents a unique proposition. First, it&rsquo;s a major automotive enterprise specializing in electric vehicles, yet it technically ranks among the OTC stocks. Second, Warren Buffett &ndash; who is best known for investing in reliable blue chips &ndash; <a href="https://www.cnbc.com/berkshire-hathaway-portfolio/">owns BYD</a> via Berkshire Hathaway (NYSE:<a href="https://investorplace.com/stock-quotes/brk-b-stock-quote/">BRK-B</a>). To be fair, Buffett has been <a href="https://apnews.com/article/berkshire-hathaway-warren-buffett-byd-397410cefd128f283c5efcc7cf90c1fa">reducing his exposure</a> but he still owns a sizable amount.



Despite the seemingly contradictory tone, investors may want to consider adding BYDDF to their portfolio. Yeah, it&rsquo;s one of the OTC stocks and yes, the Chinese economy looks rather putrid if I&rsquo;m being honest. However, with EVs becoming increasingly commoditized, guess who&rsquo;s going to win that battle? There&rsquo;s just no way that western nations can compete with their higher labor costs.



Also, investors should consider another element: demand. European politicians may want to reduce the flood of Chinese EVs. But their constituents? They love &lsquo;em. So do analysts, who rate BYDDF a <a href="https://www.tipranks.com/stocks/byddf/forecast">consensus strong buy</a> with a $36.03 price target. That implies 63% upside potential.



<h2>Xiaomi (XIACF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-charger1600-300x169.png" alt="Power supply connect to electric vehicle for charge to the battery. Charging technology industry transport which are the futuristic of the Automobile. EV fuel Plug in hybrid car."><div>Source: buffaloboy / Shutterstock.com</div></div>


Yet one more Chinese company to discuss and then we&rsquo;ll get into the really wild OTC stocks. A designer and manufacturer of consumer electronics and related software, Xiaomi (OTCMKTS:<a href="https://investorplace.com/stock-quotes/xiacf-stock-quote/">XIACF</a>) is a cynical play. For example, beyond its consumer electronics business, it&rsquo;s also involved in the EV space. Recently, the company <a href="https://www.cnbc.com/2023/12/28/chinas-xiaomi-unveils-first-ev-in-bid-to-compete-with-porsche-tesla.html">launched its first electric-powered vehicle</a>, which might have caught the eyes of some lawyers.



I&rsquo;m joking there, but seriously, the <a href="https://www.mi.com/global/discover/article?id=3095&amp;ref=upstract.com">Xiaomi SU7</a> looks like it ripped off the design of a particular German brand. But if the consumers who love BYD offer any clues, the SU7 should be a hit. Apparently, it has the performance (<a href="https://www.topspeed.com/xiaomi-su7-ev-facts/#:~:text=Performance%20Specifications&amp;text=The%20SU7%20Max%20trim%20will,top%20speed%20of%20165%20mph.">up to 664 horsepower</a>) and the longevity to <a href="https://www.carscoops.com/2023/12/xiaomis-su7-will-outrun-a-taycan-and-outlast-a-tesla-model-s/">better the top players in the ecosystem</a>. And even if you didn&rsquo;t like the EV pivot, Xiaomi should win in consumer electronics.



Frankly, with smart devices becoming so commoditized, people may start looking to price more often than brand. If so, XIACF has a clear pathway to robust shareholder profits. Analysts agree, rating the stock a <a href="https://www.tipranks.com/stocks/xiacf/forecast">unanimous strong buy</a> with a $2.66 average price target.



<h2>Quisitive Technology Solutions (QUISF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/cloud1600d-300x169.jpg" alt=""><div>Source: Shutterstock</div></div>


Okay, let&rsquo;s buckle up for some serious OTC stocks and by that, I mean high risk, high reward. First, Quisitive Technology Solutions (OTCMKTS:<a href="https://investorplace.com/stock-quotes/quisf-stock-quote/">QUISF</a>) bills itself as a premier global Microsoft (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>) partner that harnesses its cloud platforms and complete technologies to generate transformational impact for midsize and enterprise-level customers. It&rsquo;s an intriguing idea because, at one point, shares closed at $1.54 on a weekly average basis.



Currently, QUISF trades hands at only 22 cents. And you should note that over the past 52 weeks, it lost more than 53% of its equity value. Further, according to the security&rsquo;s point-and-figure (P&amp;F) chart, it prints a double bottom breakdown. According to StockCharts.com&rsquo;s educational section, this pattern is a bearish signal. That said, the pattern should also be viewed in a <a href="https://school.stockcharts.com/doku.php?id=chart_analysis:pnf_charts:pnf_bearish_bd#:~:text=for%20price%20objectives.-,Double%20Bottom%20Breakdown,These%20patterns%20are%20not%20contradictory.">broader context</a> due to possible whipsaw effects.



And what is that context? Basically, the broader cloud computing market <a href="https://www.fortunebusinessinsights.com/cloud-computing-market-102697">could be worth $2.43 trillion</a> by 2030. Quisitive just needs to take a bite out of this market to potentially drive higher. Analysts seem to be on the same page, pegging the <a href="https://www.tipranks.com/stocks/quisf/forecast">average price target at 49 cents</a>.



<h2>Peninsula Energy (PENMF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/uranium1600-300x169.jpg" alt="periodic table concept with black cubes. uranium element is glowing. Uranium stocks"><div>Source: Shutterstock</div></div>


As a fan of the uranium energy space, I perked up when I came across this opportunity hidden among OTC stocks. As a uranium extraction specialist, Peninsula Energy (OTCMKTS:<a href="https://investorplace.com/stock-quotes/penmf-stock-quote/">PENMF</a>) addresses a critical supply shortage that recently sprouted. According to The Wall Street Journal, last month, <a href="https://www.wsj.com/finance/commodities-futures/uranium-prices-jump-to-16-year-high-on-supply-woes-analysis-05c7086f">uranium prices jumped to a 16-year high</a> after one of the world&rsquo;s largest producers &ndash; Kazakhstan&rsquo;s state-owned company Kazatomprom &ndash; warned of production target shortfalls.



With uranium supplies uncertain for the next two years, several uranium players have skyrocketed. One of the exceptions is PENMF. In the trailing one-year period, the security declined by 8%. That said, it is up 15% on a year-to-date basis but that&rsquo;s a modest performance compared to exchange-listed uranium specialists.



Still, as far as OTC stocks are concerned, Peninsula could be intriguing because of geopolitical considerations. Basically, it features 100% ownership of the Lance Project, which is one of the largest uranium projects in the U.S.



Better yet, analysts expect great things, pegging shares a moderate buy with a 17-cent target. That implies almost 85% upside potential, with the high-side target landing at 22 cents.



<h2>Saturn Oil &amp; Gas (OILSF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/oilandgasstocks1600-300x169.png" alt="Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy"><div>Source: Oil and Gas Photographer / Shutterstock.com</div></div>


Based in Calgary, Alberta, Canada, Saturn Oil &amp; Gas (OTCMKTS:<a href="https://investorplace.com/stock-quotes/oilsf-stock-quote/">OILSF</a>) is a resource company engaged in the business of acquisition, exploration and development of petroleum and natural gas resource despoits in Western Canada. Further, the company&rsquo;s current focus is to advance the exploration and development of its oil and gas properties in Alberta and Saskatchewan.



As an upstream player in the hydrocarbon space, Saturn might not seem particularly relevant. Late last year, many oil-producing nations <a href="https://www.cnn.com/2023/11/30/energy/saudi-arabia-extend-production-cut-opec/index.html">agreed to cut production in a bid to bolster prices</a>. However, that effort did not succeed. Also, Reuters recently reported that rising U.S. oil production has <a href="https://www.reuters.com/markets/commodities/rising-us-oil-production-frustrates-opec-cuts-kemp-2024-02-01/">frustrated the aforementioned oil producers</a>. So, it seems OILSF could be one of the losing OTC stocks.



However, the blowout <a href="https://finance.yahoo.com/news/january-jobs-report-us-economy-adds-353000-jobs-blowing-past-wall-street-expectations-133251408.html">January jobs report</a> suggests that we shouldn&rsquo;t quite give up on black gold just yet. More people with jobs should translate to more resource consumption. And to be blunt, renewable energy just won&rsquo;t be enough to feed the growing demand profile. Notably, Echelon Wealth Partners believes OILSF <a href="https://www.tipranks.com/stocks/oilsf/forecast">could hit $4.22 per share or 137% up</a>.



<h2>Vivos (RDGL)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/medical-bills-1600-300x169.png" alt="Doctor or physician calculating a patients medical bills at a desk. Medical bills, health costs, health expenses."><div>Source: THICHA SATAPITANON / Shutterstock</div></div>


Before discussing radiation oncology medical device firm Vivos (OTCMKTS:<a href="https://investorplace.com/stock-quotes/rdgl-stock-quote/">RDGL</a>), it&rsquo;s important to disclose that I own RDGL stock. Please make a decision based on your own due diligence and a sober reflection of your risk tolerance. This is a security that has already lost almost 28% YTD and is likely subject to severe market turbulence.



With the caveats out of the way, Vivos is engaged in the development of its <a href="https://www.radiogel.com">yttrium-90-based brachytherapy device, RadioGel</a>, for the treatment of non-resectable tumors. According to Johns Hopkins Medicine, brachytherapy is a <a href="https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/brachytherapy">radiation treatment</a> that is given directly into the patient&rsquo;s body. Typically, the radiation is deployed using tiny devices such as wires, seeds, or rods filled with radioactive materials.



Where Vivos distinguishes itself is that RadioGel utilizes an injectable particle-gel, which delivers a very high local radiation dose. More broadly, RDGL entices speculators because the underlying industry is still in its early innings, <a href="https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market">worth $907.76 million in 2022</a>.



As for a price target, it&rsquo;s difficult to say as no analyst currently covers RDGL. However, <a href="https://upperdeckoptions.com/2024/01/31/rdgl-stock-a-potential-sentiment-shift-in-2023/">based on my personal research</a>, I believe around 5 cents is the bottom.



<a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a>



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&nbsp;<a href="http://investorplace.com/">InvestorPlace.com</a>&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&nbsp;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto&nbsp;held a LONG position in&nbsp;RDGL. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/high-risk-high-reward-7-otc-stocks-that-could-make-you-rich-this-year/">High-Risk, High-Reward: 7 OTC Stocks That Could Make You Rich This Year</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

High-Risk, High-Reward: 7 OTC Stocks That Could Make You Rich This Year

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you want millionaire-maker stocks, go consult Warren Buffett. The Oracle of Omaha has plenty of compelling ideas. However, if you want to reach millionaire status quickly, you&rsquo;re going to need to dial up the risk factor.



Here, the narrative is quite simple. If you want to give yourself a realistic possibility &ndash; note I didn&rsquo;t say probability &ndash; of winning big, you&rsquo;ve got to target extremely speculative market ideas. Usually, that means <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> or shares that are priced so low they can benefit from the law of small numbers.



However, once the initial liftoff is achieved, the beneficiary enterprises need attractive businesses to keep the fire burning. Arguably, the below companies have exactly that &ndash; but you better be prepared for extreme volatility. On that note, take a look at these millionaire-maker stocks.



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/kscp-stock-300x169.png" alt="An image of a Knightscope, Inc. (KSCP) robot in a parking garage"><div>Source: Sundry Photography / Shutterstock.com</div></div>Billed as a security camera and robotics firm, Knightscope (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/">KSCP</a>) designs, builds, and deploys robots called <a href="https://www.knightscope.com">Autonomous Data Robots</a>. This solution allows for the monitoring of people in malls, parking lots, neighborhoods, and other public areas. Fundamentally, the main positive catalyst for KSCP stock centers on security.



As a Californian, one news item caught my eye: the popular In-N-Out Burger will <a href="https://apnews.com/article/oakland-innout-burger-closing-crime-9cd8f43eb43fe781086b9e277eb0724d#:~:text=January%2026%2C%202024-,OAKLAND%2C%20Calif.,only%20restaurant%20in%20Oakland%2C%20California.">close its first location</a> in its 75-year history in Oakland. To the chagrin of residents, a wave of car break-ins, property damage, theft, and robberies affecting both customers and employees took their toll on the business. It&rsquo;s incidents like this multiplied at a scale that demonstrates the forward viability of KSCP as one of the millionaire-maker stocks.



To be sure, Knightscope carries significant risks, including <a href="https://www.gurufocus.com/stock/KSCP/analysis/warning-signs">several severe ones</a>, per investment data aggregator Gurufocus. Still, after a rough patch in getting the business moving, the company has printed encouraging <a href="https://www.gurufocus.com/stock/KSCP/financials">revenue growth</a> recently.



<a href="https://www.businesswire.com/news/home/20240104703804/en/Ascendiant-Capital-Markets-Maintains-Buy-Rating-for-Knightscope-Raises-Per-Share-Price-Target-to-4.00">Ascendiant&rsquo;s Edward Woo believes shares can hit $4</a>. If so, we&rsquo;re talking upside potential of over 692%.



<h2>Quantum Computing (QUBT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/quantum-computing-3-300x169.jpg" alt="A concept image showing a quantum computer with a matrix background; quantum computing. leading quantum stocks, quantum computing stocks to buy"><div>Source: Shutterstock</div></div>I love companies that explain what they do just with their title. Here on this list of millionaire-maker stocks, we have Quantum Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/qubt-stock-quote/">QUBT</a>). It doesn&rsquo;t get much more direct than that. In all seriousness, the company is pioneering the production of photonic hardware solutions using non-linear quantum optics. This innovation should allow exponential acceleration in computing, machine learning, cybersecurity and other advanced fields.



According to Fortune Business Insights, the market itself is relatively small, landing at only $928.8 million last year. However, it&rsquo;s expanding at a tremendous clip; a compound annual growth rate (CAGR) of 32.1% to 2030, per analysts&rsquo; projections. If that rate holds true, the quantum computing sector <a href="https://www.fortunebusinessinsights.com/quantum-computing-market-104855#:~:text=The%20quantum%20computing%20market%20size,share%20of%2042.97%25%20in%202022.">could be worth approximately $6.53 billion</a>.



For context, QUBT stock only printed a market capitalization of just under $59 million. So, if the stars align, Quantum could easily rank among the millionaire-maker stocks.



Sure enough, <a href="https://finance.yahoo.com/news/7-analyst-backed-stocks-promising-000957206.html">Ascendiant&rsquo;s Woo also endorses QUBT, targeting $8.75</a> or around 1,015% up from Wednesday&rsquo;s close.



<h2>Vivos (RDGL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>If you want to know what a dedicated fanbase for a publicly traded security looks like, <a href="https://twitter.com/EnomotoMedia">check out my X account</a>. Here, you&rsquo;re going to find plenty of discussions and expressions of adoration for medical technology firm Vivos (OTCMKTS:<a href="https://investorplace.com/stock-quotes/rdgl-stock-quote/">RDGL</a>). Yes, it&rsquo;s traded over the counter. Yes, it&rsquo;s a six-cent stock. No, it&rsquo;s not something out of the movie &ldquo;The Wolf of Wall Street.&rdquo;



Instead, what we have here is a radiation oncology specialist. Focusing on an advanced form of brachytherapy, Vivos utilizes radioactive materials (yttrium-90) to directly implement a high-dose treatment to the target area while imposing a minimal dosage to surrounding healthy tissue. Brachytherapy is already a promising therapeutic approach, which should see a 7.1% CAGR <a href="https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market">to land at a value of $1.62 billion by 2030</a>.



Here&rsquo;s what&rsquo;s really intriguing about Vivos: it improves upon brachytherapy through a minimally invasive procedure that leverages a hydrogel solution to deliver the cancer-fighting therapeutic. Following the implementation, the hydrogel is safely absorbed by the body. Vivos appears unique in its brachytherapy-based approach. Therefore, I have personally put my money where my mouth is here.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto&nbsp;held a LONG position in RDGL. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/3-stocks-to-turn-1000-into-1-million-february-2024/">3 Stocks to Turn $1,000 Into $1 Million: February 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Stocks to Turn $1,000 Into $1 Million: February 2024

Vivos Inc (RDGL) has issued an update. Vivos, Inc. has renewed its Executive Employment Agreement with CEO Dr. Michael Korenko, effective January 1...

Vivos Inc Secures Leadership Continuity with CEO Contract Renewal

Catalyst Watch: Disney earnings, Apple iPad event and Fed speakers back on the circuit

AAPL

AMCX

ASCUF

AZTR

BYDDF

BYND

CABA

COST

CPNG

CPRI

CRSP

DCPH

DDOG

EDIT

FGEN

KNSL

KOPN

KSCP

LAZR

MBLY

MCBC

MNST

MSFT

NDAQ

NISTF

NKLA

NRGV

OILSF

PENMF

PLTR

QUBT

QUISF

RACE

RBLX

RDDT

RDGL

REGN

RIVN

SAVE

SHOP

SNAP

TCEHY

TSLA

UBER

UPST

USFD

VRTX

VSTO

VZIO

XIACF

ZYXI

Screenshot 2024-07-01 at 8.57.06 AM

Biotech

General

Vivos One Step Closer To Transforming Cancer Treatment With FDA Application To Start Human Trials For Pioneering Injectable Brachytherapy Device

Press Releases

Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation

Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials

Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA

Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics

Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM

Vivos

Comments

Vivos

Vendite allo scoperto

Vivos (OTC:RDGL) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO